Search Results

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.

SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe.

Vaxxas announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.